Increased mutability to fosfomycin resistance in Proteus mirabilis clinical isolates

被引:6
|
作者
Fonseca, Marina R. B. [1 ]
Sato, Juliana L. [1 ]
Lima-Noronha, Marco A. [1 ]
Migliorini, Leticia B. [1 ]
Fernandez-Silva, Frank S. [1 ]
Galhardo, Rodrigo S. [1 ]
机构
[1] Univ Sao Paulo, Inst Biomed Sci, Dept Microbiol, Sao Paulo, SP, Brazil
基金
巴西圣保罗研究基金会;
关键词
Mutators; Mutagenesis; Fosfomycin resistance; Proteus mirabilis; ELEMENTS CARRYING BLA(CMY-2); URINARY-TRACT-INFECTION; ESCHERICHIA-COLI; MUTATION FREQUENCIES; BETA-LACTAMASE; EMERGENCE; SUSCEPTIBILITY; PREVALENCE; MECHANISMS; MUTATORS;
D O I
10.1016/j.meegid.2017.12.012
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
In the present study, we screened a collection of 77 Proteus mirabilis clinical isolates for the presence of mutators, using the frequency of both rifampicin and fosfomycin resistance mutants as markers of spontaneous mutagenesis. We found that none of the strains in our collection are mutators for the rifampicin resistance (Rif(R)) marker. Nevertheless, a significant fraction of the isolates (17%) show high frequencies of fosfomycin resistant mutants (Fos(R)). We show that this increased mutability to FosR correlates with a low level of resistance to Fosfomycin (MICs 8-64 mu g/ml). These strains also show high frequencies of single step mutants with clinically relevant FosR resistance levels (MIC >= 256 mu g/ml). Our findings point out to the risk of fosfomycin resistance emergence in P. mirabilis.
引用
收藏
页码:27 / 33
页数:7
相关论文
共 50 条
  • [21] IMIPENEM RESISTANCE IN PROTEUS-MIRABILIS
    MEHTAR, S
    TSAKRIS, A
    PITT, TL
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1991, 28 (04) : 612 - 615
  • [22] Multidrug resistance by biofilm-forming clinical strains of Proteus mirabilis
    Sahal, Gulcan
    Bilkay, Isil Seyis
    ASIAN BIOMEDICINE, 2015, 9 (04) : 535 - 541
  • [23] SEPARATE O-GROUPING SCHEMES FOR SEROTYPING CLINICAL ISOLATES OF PROTEUS-VULGARIS AND PROTEUS-MIRABILIS
    PENNER, JL
    HENNESSY, JN
    JOURNAL OF CLINICAL MICROBIOLOGY, 1980, 12 (03) : 304 - 309
  • [24] Prevalence of extended-spectrum β-lactamases, AmpC, and carbapenemases in Proteus mirabilis clinical isolates
    Mona Shaaban
    Soha Lotfy Elshaer
    Ola A. Abd El-Rahman
    BMC Microbiology, 22
  • [25] Prevalence of extended-spectrum β-lactamases, AmpC, and carbapenemases in Proteus mirabilis clinical isolates
    Shaaban, Mona
    Elshaer, Soha Lotfy
    Abd El-Rahman, Ola A.
    BMC MICROBIOLOGY, 2022, 22 (01)
  • [26] Distribution and Molecular Characterization of Functional Class 2 Integrons in Clinical Proteus mirabilis Isolates
    Lu, Wenjun
    Qiu, Quedan
    Chen, Keda
    Zhao, Rongqing
    Li, Qingcao
    Wu, Qiaoping
    INFECTION AND DRUG RESISTANCE, 2022, 15 : 465 - 474
  • [27] Comparison of PCR-Based Molecular Markers for the Characterization of Proteus mirabilis Clinical Isolates
    Michelim, Lessandra
    Muller, Gabriela
    Zacaria, Jucimar
    Longaray Delamare, Ana Paula
    Pinto da Costa, Sergio Olavo
    Echeverrigaray, Sergio
    BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2008, 12 (05): : 423 - 429
  • [28] Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli
    Takahata, Sho
    Ida, Takashi
    Hiraishi, Toru
    Sakakibara, Shiro
    Maebashi, Kazunori
    Terada, Shinichi
    Muratani, Tetsuro
    Matsumoto, Tetsuro
    Nakahama, Chikara
    Tomono, Kazunori
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2010, 35 (04) : 333 - 337
  • [29] Clinical features of Proteus mirabilis pneumonia
    Okimoto, Niro
    Hayashi, Toshikiyo
    Ishiga, Mitsunori
    Nanba, Fumiyo
    Kishimoto, Michihiro
    Yagi, Shinichi
    Kurihara, Takeyuki
    Asaoka, Naoko
    Tamada, Sadao
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2010, 16 (05) : 364 - 366
  • [30] Identification of AbaR4 Acinetobacter baumannii resistance island in clinical isolates of blaOXA-23-positive Proteus mirabilis
    Octavia, Sophie
    Xu, Weizhen
    Ng, Oon Tek
    Marimuthu, Kalisvar
    Venkatachalam, Indumathi
    Cheng, Bernadette
    Lin, Raymond T. P.
    Teo, Jeanette W. P.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (03) : 521 - 525